- Home
- NVS vs TMO Comparison
NVS vs TMO Comparison
Compare NVS & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | TMO |
|---|---|---|
| Founded | 1895 | 1956 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.5B | 216.4B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVS | TMO |
|---|---|---|
| Price | $141.51 | $614.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $118.00 | ★ $633.33 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 01-30-2026 | 01-29-2026 |
| Dividend Yield | ★ 1.83% | 0.28% |
| EPS Growth | N/A | ★ 8.54 |
| EPS | 7.30 | ★ 17.32 |
| Revenue | ★ $56,372,000,000.00 | $43,736,000,000.00 |
| Revenue This Year | $9.38 | $4.33 |
| Revenue Next Year | $2.69 | $4.98 |
| P/E Ratio | ★ $19.45 | $35.64 |
| Revenue Growth | ★ 12.88 | 3.22 |
| 52 Week Low | $97.39 | $385.46 |
| 52 Week High | $143.49 | $628.08 |
Technical Indicators
Market Signals| Indicator | NVS | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 69.22 |
| Support Level | $135.55 | $577.00 |
| Resistance Level | $143.49 | $628.08 |
| Average True Range (ATR) | 1.56 | 10.66 |
| MACD | 0.23 | 4.45 |
| Stochastic Oscillator | 77.06 | 82.62 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).